Primus In News
Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts
29-06-2025
Nilaya Varma, Group CEO and Co-founder, Primus Partners, shared his view on the changing landscape of the global generics industry. He highlighted that India's pharmaceutical exports have grown significantly—from $15 billion in 2013–14 to nearly $28 billion over the last decade—driven by the country’s 750+ USFDA-approved facilities and expanding expertise in complex generics and biosimilars. With major global players scaling down operations, Indian companies are well-placed to seize the $180 billion loss-of-exclusivity opportunity
Explore Related Insights
- Karnataka to hire consultant to monitor schemes under startup policy
- Stock Market, 3 Nov Highlights: Sensex, Nifty end flat, check top gainers and losers | Closing Bell | Report
- India’s infra ambitions to get a new X factor: The military
- India’s rare earth magnet crisis: The road ahead for domestic EV companies
